SHANGHAI-Ruder Finn(罗德公关) has won 12 Healthcare projects since the beginning of the year, in competition with international and local agencies in Shanghai, Beijing and Guangzhou. The list of new clients includes Astellas Pharma, AstraZeneca, Mead Johnson, Merck Sharp & Dohme (MSD), Roche, Wyeth, Sandoz and Schering Plough Pharmaceuticals. The projects range from a corporate positioning retainer to media training, product communication to media outreach and also event management.

Ruder Finn has more than 10 years experience and expertise in healthcare communications in China and has established a strong reputation in the pharmaceutical industry.

“We have a dedicated and hardworking team in our healthcare sector, and with our long term experience and expertise in this industry, we are able to understand a client’s needs and concerns,” said Liu Cheng, VP Healthcare, Ruder Finn. “Pharmaceutical companies play a major part in people’s lives and we are proud to work with them.”

The new China wins expand Ruder Finn’s already impressive client roster in Asia Pacific, which includes Novartis, MSD, Parkway Healthcare and Elsevier, among others.

“Winning these diverse projects truly validates Ruder Finn’s Global Health & Wellness Platform. With our strong regional and global network and solid media relations track record, we are able to leverage our expertise in healthcare communications to help clients make a significant contribution to the well-being of consumers in China, “said Jean Michel Dumont, Chairman, Ruder Finn Asia.

In China, sales of over the counter drugs are very much driven by advertising and mass media publicity. Prescription drugs face a lot of restrictions as Chinese law does not allow advertising or the mention of brand names in promotions. With such restrictions on prescription drugs, the role of healthcare PR is critical since there are no other effective means for pharmaceutical companies to reach their consumers. In this environment, PR becomes an important tool to educate patients about medical conditions and treatment.

By: MiColChan


这篇文章上的评论的RSS feed


© 2006-2019 | 京ICP备16010340号